ThromboGenics

Type: Company

Name: ThromboGenics

First reported May 16 2013 - Updated May 16 2013 - 1 reports

ThromboGenics Business Update

/PRNewswire/ -- JETREA®gaining acceptance from the US retina community. US sales through end of April 2013 have exceeded $10 million Phase IIa study evaluating JETREA... ... [Published FinanzNachrichten.de - May 16 2013]

Entities: ThromboGenics, Phase II

First reported May 16 2013 - Updated May 16 2013 - 1 reports

ThromboGenics says U.S. sales of Jetrea top $10 million

4:52pm BSTBRUSSELS, May 16 (Reuters) - Belgian drug developer ThromboGenics said on Thursday U.S. sales of its eye drug Jetrea have exceeded $10 million, after the drug was launched there at the start of the year.ThromboGenics, whose drug Jetrea was launched ... [Published Reuters UK - May 16 2013]

Entities: ThromboGenics, Drugs, United States, Adrian Croft

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Ahead of the curve

Flanders has become a real hub for biotechnology, with half the biotech shares traded these days on the Euronext stock exchange belonging to companies based here. So what exactly is biotech, and what’s the secret of the region’s success?Last month, more ... [Published Flanders Today - May 15 2013]

Entities: Biotechnology, ThromboGenics, Drugs, Flemish

First reported May 09 2013 - Updated May 09 2013 - 1 reports

ResearchMoz.us: Angiogenesis Inhibitors and Stimulators Market: Global Trends and Forecast 2012-2018

The process of formation of new blood vessel from the existing blood vessel by intussusceptive or budding is termed as Angiogenesis. And hence it places a crucial role in growth and renewal of body tissues in order to maintain wear and tear of the body ... [Published MyNewsDesk - May 09 2013]

Entities: angiogenesis, Market, Celltech Group plc, OSI Pharmaceuticals Inc

First reported May 02 2013 - Updated May 03 2013 - 2 reports

ThromboGenics’ JETREA® Available in Germany Public and Private Market

Company could receive a further €210 million in milestones plus significant royalties. ... [Published Technology Networks - May 03 2013]

Entities: ThromboGenics, Market, Germany

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Jetrea released in the UK April 17 2013 Drug on the UK market before the rest of Europe

Vision UK 2013 ConferenceVIsion UK 2013 conference to be held in London on June 11Job TipsOT's dedicated Job Tips hub offers you free help and advice for when you are searching for your next career move. It includes handy hints on how to write a cover ... [Published Optometry Today - Apr 17 2013]

Entities: United Kingdom, Drugs, ThromboGenics, Alcon Inc, Biopharmaceutical

First reported Apr 12 2013 - Updated Apr 12 2013 - 1 reports

Alcon Inc

Alcon launches first medicine to treat vitreomacular traction in UK

ThromboGenics' partner Alcon has launched Jetrea (ocriplasmin), the first and only medicine for the treatment of vitreomacular traction (VMT) in the UK. ... [Published PBR - News - Apr 12 2013]

Entities: Alcon Inc, United Kingdom, ThromboGenics

First reported Mar 18 2013 - Updated Mar 18 2013 - 1 reports

ThromboGenics Jetrea wins approval for vitreomacular traction treatment in Europe

The European Commission has approved ThromboGenics' Jetrea (ocriplasmin) for the treatment of vitreomacular traction (VMT), including when coupled with macular hole of diameter less than or equal to 400 microns, in the European Union (EU). ... [Published PBR - News - Mar 18 2013]

Entities: ThromboGenics, European Union, European Commission

First reported Jan 19 2013 - Updated Jan 19 2013 - 1 reports

Novartis' Jetrea receives positive CHMP opinion to treat sight-threatening VMT and macular hole

Alcon, the global leader in eye care and a division of Novartis, has received the positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Jetrea (ocriplasmin), for the treatment of vitreomacular ... [Published PharmaBiz - Jan 19 2013]

Entities: Novartis AG, Alcon Inc, Retinal, ThromboGenics

Quotes

...hole and for whom there has been limited prospect of treatment," said Sabri Markabi, senior vice president, Research and Development at Alcon. "This demonstrates Alcon's steadfast commitment to addressing unmet patient needs in the field of eye care. Europe will be the first region outside the US where we expect Jetrea to be approved and our goal is to make this treatment accessible to many more patients around the world."

Novartis' Jetrea receives positive CHMP opinion to treat sight-threatening VMT and macular hole [Published PharmaBiz - Jan 19 2013]

Fujifilm Diosynth Biotechnologies Billingham managing director Steve Bagshaw said, "This is fifth licensed biopharmaceutical manufactured by Fujifilm Diosynth Biotechnologies and the second made at our Billingham site, demonstrating our growing expertise in helping to transition biopharmaceuticals from the clinic to become marketed new drugs" . Jetrea is an enzyme that breaks down proteins that lead to VMA in the eye

Fujifilm to manufacture bulk substance for ThromboGenics' eye medication [Published Pharmaceutical Business Review - Nov 16 2012]

More Content

sort by: Date \| Relevance
Competitor Analysis: Thrombolytics & Fibrinolytics [Published Individual.com - May 20 2013]
ThromboGenics Business Update [Published FinanzNachrichten.de - May 16 2013]
ThromboGenics says U.S. sales of Jetrea top $10... [Published Reuters UK - May 16 2013]
Ahead of the curve [Published Flanders Today - May 15 2013]
ResearchMoz.us: Angiogenesis Inhibitors and Sti... [Published MyNewsDesk - May 09 2013]
ThromboGenics’ JETREA® Available in Germany Pub... [Published Technology Networks - May 03 2013]
ThromboGenics' JETREA® Available in Germany Pub... [Published NewsBlaze - May 02 2013]
Jetrea released in the UK April 17 2013 Drug on... [Published Optometry Today - Apr 17 2013]
Optical Coherence Tomography In Macular Hole Ma... [Published Retinal Physician - Apr 17 2013]
Does Surgery Have a Future in Retina Care? [Published Retinal Physician - Apr 17 2013]
Alcon launches first medicine to treat vitreoma... [Published PBR - News - Apr 12 2013]
ThromboGenics Jetrea wins approval for vitreoma... [Published PBR - News - Mar 18 2013]
JETREA®: The first Non-surgical treatment of Vi... [Published PRWeb - Feb 06 2013]
Positive results from the BI-505 phase I study ... [Published CisionWire - English - Jan 24 2013]
Novartis' Jetrea receives positive CHMP opinion... [Published PharmaBiz - Jan 19 2013]
ThromboGenics Receives Positive CHMP Opinion fo... [Published PR Newswire: General Business - Jan 18 2013]
Investment Research Weekly Roundup including bl... [Published Proactiveinvestors United Kingdom RSS feed - Jan 18 2013]
A Big Year for Novel Drugs Approvals [Published I Am Biotech - Jan 17 2013]
Telenet CEO puts shares into autonomous blind t... [Published Telecompaper - Dec 03 2012]
Study Poses Question About Safe Level of VEGF R... [Published Review of Ophthalmology - Nov 21 2012]
Fujifilm to manufacture bulk substance for Thro... [Published Pharmaceutical Business Review - Nov 16 2012]
VMA treatment approved [Published Modern Medicine - Oct 24 2012]
ThromboGenicsâ Jetrea receives US FDA approval ... [Published PharmaBiz - Oct 19 2012]
ThromboGenics publishes phase III data of ocrip... [Published BioPortfolio - Aug 18 2012]